AstraZeneca Eyes Bristol Myers Squibb in Potential $400bn Deal

AstraZeneca is in talks to acquire US rival Bristol Myers Squibb, the Financial Times reported on 3 August 2026, citing unnamed sources. A deal would create a near-$400bn drugmaker — the world's fourth-largest by market value. Months of talks may not conclude. AstraZeneca's shares fell over 7% on the news.